Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Verbruggen

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of Thrombosis and Haemostasis : JTH|August 23, 2011
The factor VIII inhibitor assays can be standardized: results of a workshopB Verbruggen, M Dardikh, R Polenewen, et al.
Thrombosis and Haemostasis|January 5, 2002
The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitorsB Verbruggen, A Giles, J Samis, et al.
Thrombosis and Haemostasis|May 6, 1998
A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and HaemostasisA R Giles, B Verbruggen, G E Rivard, et al.
Thorax|October 20, 1999
Effect of oral L-arginine on airway hyperresponsiveness to histamine in asthmaH W de Gouw, M B Verbruggen, I M Twiss, et al.
Biotechnology Progress|April 21, 2001
A quantitative approach to characterizing cell lysis caused by mechanical agitation of Streptomyces clavuligerusJ A Roubos, P Krabben, R G Luiten, et al.
Clinical Pharmacology and Therapeutics|November 5, 1999
Meloxicam, 15 mg/day, spares platelet function in healthy volunteersA de Meijer, H Vollaard, M de Metz, et al.
Thrombosis and Haemostasis|February 1, 1995
The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliabilityB Verbruggen, I Novakova, H Wessels, et al.
Journal of Thrombosis and Haemostasis : JTH|January 31, 2012
Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance inductionM Dardikh, T Albert, R Masereeuw, et al.
Blood|April 16, 1998
Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosisL A Kluijtmans, G H Boers, B Verbruggen, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|June 10, 2000
Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathyE F van der Molen, B Verbruggen, I Nováková, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of Thrombosis and Haemostasis : JTH|August 23, 2011
The factor VIII inhibitor assays can be standardized: results of a workshopB Verbruggen, M Dardikh, R Polenewen, et al.
Thrombosis and Haemostasis|January 5, 2002
The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitorsB Verbruggen, A Giles, J Samis, et al.
Thrombosis and Haemostasis|May 6, 1998
A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and HaemostasisA R Giles, B Verbruggen, G E Rivard, et al.
Thorax|October 20, 1999
Effect of oral L-arginine on airway hyperresponsiveness to histamine in asthmaH W de Gouw, M B Verbruggen, I M Twiss, et al.
Biotechnology Progress|April 21, 2001
A quantitative approach to characterizing cell lysis caused by mechanical agitation of Streptomyces clavuligerusJ A Roubos, P Krabben, R G Luiten, et al.
Clinical Pharmacology and Therapeutics|November 5, 1999
Meloxicam, 15 mg/day, spares platelet function in healthy volunteersA de Meijer, H Vollaard, M de Metz, et al.
Thrombosis and Haemostasis|February 1, 1995
The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliabilityB Verbruggen, I Novakova, H Wessels, et al.
Journal of Thrombosis and Haemostasis : JTH|January 31, 2012
Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance inductionM Dardikh, T Albert, R Masereeuw, et al.
Blood|April 16, 1998
Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosisL A Kluijtmans, G H Boers, B Verbruggen, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|June 10, 2000
Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathyE F van der Molen, B Verbruggen, I Nováková, et al.
Pageof 3